Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

IXI:LN

35.000 GBp 0.500 1.45%

As of 06:00:06 ET on 03/02/2015.

Snapshot for IXICO PLC (IXI)

Open: 34.500 Day's Range: 34.500 - 35.000 Volume: 25,000
Previous Close: 34.500 52wk Range: 34.000 - 85.500 1-Yr Rtn: -48.15%

Stock Chart for IXI

No chart data available.
  • IXI:LN 35.000
  • 1D
  • 1M
  • 1Y
34.500
Interactive IXI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for IXI

Current P/E Ratio (ttm) -
Estimated P/E(09/2015) -
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) -0.4100
Est. EPS (GBP) (09/2015) -0.1240
Est. PEG Ratio -
Market Cap (M GBP) 5.27
Shares Outstanding (M) 15.06
30 Day Average Volume 7,623
Price/Book (mrq) 1.1267
Price/Sale (ttm) 4.1406
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 06/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for IXI

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for IXI

IXICO plc offers technologies for researching, diagnosing and treating serious diseases with a focus on neuro-degeneration. The technologies include medical image management and analysis products to assess the safety and efficacy of drugs in development. The Company's proprietary technologies TrialWire(tm) and TrialTracker(tm) have been used in clinical trials of Alzheimer's treatments.

Derek HillChief Executive OfficerSusan Day LowtherChief Financial Officer
Jane WhitrowVP:Business Ops/SecretaryJohn HallVP:Business Development
More Company Profile & Key Executives for IXI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil